Glioblastoma Multiforme Market Research Report 2032: Treatment Market, Epidemiology Data, Therapies, Companies and Competitive Analysis by DelveInsight

PRESS RELEASE
Published April 4, 2023

(Albany, USA) DelveInsight’s Glioblastoma Multiforme Market Insights report includes a comprehensive understanding of current treatment practices, glioblastoma multiforme emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

To know more about the Glioblastoma Multiforme Market Report offerings, click here @ Glioblastoma Multiforme Market Forecast

Key Takeaways from the Glioblastoma Multiforme Market Report

  • As per DelveInsight analysis, the glioblastoma multiforme market size in the 7MM was approximately USD 799 million in 2021.
  • According to the assessment done by DelveInsight, the estimated total glioblastoma multiforme incident cases in the 7MM were approximately 5K in 2021.
  • Leading glioblastoma multiforme companies such as Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Biotherapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, Novocure, Genentech, Daiichi Sankyo, Novartis, and others are developing novel glioblastoma drugs that can be available in the glioblastoma multiforme market in the coming years.
  • The promising glioblastoma multiforme therapies in the pipeline include Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.
  • The current therapeutic landscape of GBM in the United States is driven by the current treatment paradigm, which includes therapies such as radiation, bevacizumab, temozolomide, and OPTUNE, as mono or combination therapies, as well as several other systemic therapies.
  • In October 2022, NovAccess Global’s TLR-AD1 Orphan Drug Application was approved by the FDA. The FDA broadens the scope of the company’s submission, accelerating the path to immunotherapy for glioblastoma.
  • In October 2022, Black Diamond Therapeutics announced the presentation of three posters reporting new preclinical data on BDTX-1535 and BDTX-4933 at the 34th European Organization for Research and Treatment of Cancer—National Cancer Institute—American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
  • In October 2022, Oblato, a Korean subsidiary of HLB Therapeutics, announced that it has completed enrollment of recurrent GBM patients in Phase II clinical trial with its proprietary compound OKN-007 in the United States.
  • In August 2022, Northwest Biotherapeutics announced that the Pediatric Investigation Plan (PIP) had been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The company’s approved PIP includes two clinical trials: one for newly diagnosed pediatric HGG, and one for recurrent pediatric HGG. In each of the two pediatric trials, 24 patients will be treated with DCVax-L on the same treatment schedule as in the company’s Phase III trial in adult glioblastoma patients.

Discover which therapies are expected to grab the major glioblastoma multiforme market share @ https://www.delveinsight.com/sample-request/glioblastoma-market

Glioblastoma Multiforme Overview

Glioblastoma, also known as glioblastoma multiforme is cancer that can develop in the brain or spinal cord. Glioblastoma develops from astrocytes, which are nerve cell-feeding cells. It can occur at any age, but it is more common in the elderly. It can make headaches, nausea, vomiting, and seizures worse. The causes of glioblastoma are unknown.

Glioblastoma symptoms vary depending on tumor type, size, location, and growth rate. Headache, nausea or vomiting, confusion or deterioration in brain function, memory loss, personality changes or irritability, and difficulty balancing are all common glioblastoma symptoms. Computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI) are two diagnostic tools used for glioblastoma diagnosis. Glioblastoma treatments may slow cancer progression and alleviate symptoms.

Glioblastoma Multiforme Epidemiology Segmentation

DelveInsight estimates that there were approximately 32.5K incident cases of glioblastoma multiforme in the 7MM in 2021.

Among the EU-4 countries, the incident population of GBM was found to be the maximum in Germany in 2021.

The glioblastoma multiforme market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Incident Cases
  • Gender-specific Incident Cases
  • Type-specific Incident Cases
  • Age-specific Incident Cases
  • Incident Cases based on the Primary Site of GBM
  • Incident Cases based on Histologic Classification of GBM

Download the report to understand which factors are driving glioblastoma multiforme epidemiology trends @ https://www.delveinsight.com/sample-request/glioblastoma-market

Glioblastoma Multiforme Treatment Market 

Glioblastoma multiforme is typically treated with a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Although rarely used alone, surgery is usually one of the most important aspects of glioblastoma treatment. Because glioblastomas grow so quickly, they are frequently difficult to remove completely. As a result, surgery is performed to achieve the best possible safe resection – removing as much of the tumor as possible while preserving brain function and sparing healthy tissues. Following surgery, residual cancer cells can be targeted with additional treatments such as chemotherapy or radiation therapy. Once the tumor’s diagnosis or name is determined, radiation therapy and chemotherapy are usually administered.

These are known as adjuvant glioblastoma treatments. Because this multispecialty approach can have several side effects, steroids are frequently used as an additional component of glioblastoma treatment to help alleviate the side effects of other therapies.

Chemotherapy is a common type of glioblastoma treatment. Patients typically begin chemotherapy 2-4 weeks after surgery, at the same time as or shortly after radiation therapy. When a tumor cannot be surgically removed, chemotherapy is sometimes used as the primary glioblastoma treatment.

Cytotoxic drugs include Carmustine (BCNU), Lomustine (CCNU), or Gleostine (Generic), Gliadel wafer (biodegradable discs infused with BCNU), Temozolomide (Temodar), Cisplatin, Carboplatin, Etoposide, and Irinotecan.

To know more about glioblastoma treatment options, visit @ https://www.delveinsight.com/sample-request/glioblastoma-market

Glioblastoma Multiforme Pipeline Therapies and Key Companies

  • Regorafenib: Bayer
  • ONC201: Chimerix
  • AV-GBM-1: Aivita Biomedical
  • Enzastaurin (DB-102): Denovo Biopharma
  • DCVax-L: Northwest Biotherapeutics
  • Ofranergene Obadenovec (VB-111): VBL Therapeutics
  • LAM561 (2-OHOA): Laminar Pharmaceuticals
  • MEDI4736 (durvalumab): MedImmune
  • Tasadenoturev (DNX-2401): DNAtrix
  • ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
  • IGV-001: Imvax
  • SurVaxM: MimiVax
  • Berubicin: CNS Pharmaceuticals
  • GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
  • Lerapolturev + Pembrolizumab: Istari Oncology
  • SONALA-001 + Exablate 2.0 Device: SonALAsense
  • VAL-083 (dianhydrogalactitol): Kintara Therapeutics
  • Pomalidomide: Bristol Myers Squibb
  • MDNA55: Medicenna Therapeutics
  • BMX-001: BioMimetix
  • Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
  • Paxalisib (GDC-0084): Kazia Therapeutics
  • OKN-007: Oblato
  • Temferon: Genenta Science
  • EO2401: Enterome
  • INO-5401 + INO-9012 + LIBTAYO (cemiplimab): Inovio Pharmaceuticals
  • Selinexor (KPT-330): Karyopharm Therapeutics
  • Olutasidenib (FT-2102): Forma Therapeutics
  • VBI-1901: VBI Vaccines
  • Olaptesed pegol (NOX-A12): TME Pharma

Learn more about the glioblastoma FDA-approved drugs @ https://www.delveinsight.com/sample-request/glioblastoma-market

Scope of the Glioblastoma Multiforme Market Report

  • Therapeutic Assessment: Glioblastoma Multiforme current marketed and emerging therapies
  • Glioblastoma MultiformeMarket Dynamics: Glioblastoma Multiforme market drivers and barriers
  • Competitive Intelligence Analysis:SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Glioblastoma Multiforme Market Access and Reimbursement
  • Key Glioblastoma Multiforme Companies: Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Biotherapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, Novocure Limited, Genentech, Daiichi Sankyo, Novartis, and others
  • Key Pipeline Glioblastoma Multiforme Therapies: Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12/olaptesed pegol, and others.

Discover more about glioblastoma drugs in development @ https://www.delveinsight.com/sample-request/glioblastoma-market

Table of Contents

1 Key Insights

2 Report Introduction

3 Glioblastoma Multiforme Market Overview at a Glance

3.1 Market Share (%) Distribution of GBM in 2019 by Countries

3.2 Market Share (%) Distribution of GBM in 2032 by Countries

4 Epidemiology and Market Forecast Methodology

5 Executive Summary of Glioblastoma Multiforme (GBM)

6 Key Events

7 SWOT Analysis

8 Disease Background and Overview: Glioblastoma Multiforme

8.1 Introduction

8.2 Classification of Glioblastoma Multiforme

8.3 Glioblastoma Types

8.4 Symptoms

8.5 Pathophysiology

8.6 Inheritance of Glioblastoma Multiforme

8.7 Molecular Classification

8.8 Diagnosis of Glioblastoma Multiforme

9 Treatment

10 Guidelines and Recommendations from Different Organizations

11 Epidemiology and Patient Population

12 Patient Journey

13 Key Endpoints in Glioblastoma Multiforme

14 Marketed Products

14.1 Key Competitors

15 Emerging Drugs

15.1 Key Competitors

16 GBM: Seven Major Market Analysis

17 KOL Views

18 Unmet Needs

19 Market Access and Reimbursement

20 Appendix

20.1 Bibliography

20.2 Report Methodology

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight

Discover more about glioblastoma drugs in development @ https://www.delveinsight.com/sample-request/glioblastoma-market

New Reports Launched:

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Contact Us:

Ankit Nigam

info@delveinsight.com

+1(919)321-6187

https://www.delveinsight.com/consulting

Newsmantraa